Invanz

Invanz

ertapenem

Manufacturer:

Merck Sharp & Dohme

Distributor:

Zuellig
Concise Prescribing Info
Contents
Ertapenem
Indications/Uses
Patients w/ moderate to severe infections caused by susceptible strains of microorganisms, as well as initial empiric therapy prior to the identification of causative organisms in adults & ped patients 3 mth-17 yr w/ complicated intra-abdominal infections; complicated skin & skin structure infections including diabetic lower extremity infection (diabetic foot infection in adults); community-acquired pneumonia; complicated UTI including pyelonephritis; acute pelvic infections including postpartum endomyometritis, septic abortion & postsurgical gynecologic infections; bacterial septicemia (in adults). Prophylaxis of surgical site infection following elective colorectal surgery in adults.
Dosage/Direction for Use
IV/IM Patient ≥13 yr 1 g once daily. Patient 3 mth-12 yr 15 mg/kg bid. Max: 1 g daily. IV should be infused over 30-min period. Usual duration of therapy: 3-14 days depending on type of infection & causative pathogen(s). Adult Prophylaxis of surgical site infection following elective colorectal surgery 1 g as a single IV dose given 1 hr prior to surgical incision. Advanced renal insufficiency (CrCl ≤30 mL/min/1.73 m2) including those on hemodialysis 500 mg daily. Patient on hemodialysis 500 mg given w/in 6 hr prior to hemodialysis, then a supplementary dose of 150 mg following the hemodialysis session. No supplementary dose is needed if given at least 6 hr prior to hemodialysis.
Contraindications
Hypersensitivity to ertapenem or other carbapenems. Patients who had anaphylactic reactions to β-lactams. IM administration in patients w/ hypersensitivity to amide-type local anesth. Patients w/ severe shock or heart block.
Special Precautions
Previous hypersensitivity to penicillins, cephalosporins, other β-lactams & other allergens. Seizures & other CNS adverse event in patients w/ CNS disorders (eg, brain lesions or history of seizures) &/or compromised renal function. Overgrowth of non-susceptible organisms w/ prolonged use; superinfection may occur during therapy. Pseudomembranous colitis. IM administration & use of lidocaine HCl as diluent. Concomitant use w/ valproic acid/divalproex Na is not recommended. Pregnancy & lactation. Not recommended in infants <3 mth.
Adverse Reactions
Diarrhea, vomiting. Adult: Headache; infused vein complication, phlebitis/thrombophlebitis; nausea. Ped: Infusion site erythema/pain/phlebitis/ swelling; rash.
Drug Interactions
Inhibited renal excretion w/ probenecid. Reduced conc of valproic acid or divalproex Na below the therapeutic range.
MIMS Class
Other Beta-Lactams
ATC Classification
J01DH03 - ertapenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.
Presentation/Packing
Form
Invanz powd for inj 1 g
Packing/Price
1's (P3,325/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in